Why the study?
Empagliflozin improves heart failure outcomes, but its effect on vascular cell function and vascular remodeling processes remained largely elusive.
Does empagliflozin prevent neointima formation and improve endothelial regeneration in vascular injury models?
Population
Human SMCs and ECs, C57BL/6J mice, and streptozocin-induced diabetic apolipoprotein E -/- mice
Comparison
Empagliflozin treatment vs control
Design
Preclinical in vitro and in vivo animal study
Follow-up
3 days
Key result
Empagliflozin reduced smooth muscle cell proliferation in vitro and prevented neointima formation in vivo, while augmenting endothelial cell proliferation and re-endothelialization.
Authors
Loading...
Hypothesis-generating for vascular benefits in injury models; leaves open translation to human restenosis prevention.
Does empagliflozin prevent neointima formation and improve endothelial regeneration in vascular injury models?
Empagliflozin prevents neointima formation and promotes re-endothelialization after vascular injury in preclinical models, suggesting a direct beneficial vascular effect.
Dutzmann et al. (2022) studied vascular remodeling. Empagliflozin was evaluated on neointima formation and endothelial regeneration. Empagliflozin reduced smooth muscle cell proliferation in vitro and prevented neointima formation in vivo, while augmenting endothelial cell proliferation and re-endothelialization.